SKLB-C05

• Description:

  SKLB-C05 is a novel selective, orally active TOPK inhibitor, with an IC50 of 0.5 nM. SKLB-C05 selectively inhibit TOPK kinase. SKLB-C05 induces Apoptosis, downregulates c-Myc, γ-H2AX, activates p53, blocks FAK/Src medicated migration-related signaling. SKLB-C05 disturbs cell mitosis. SKLB-C05 shows anticancer activity only against TOPK-positive colorectal cancer[1].

• UNSPSC:

  12352005

• Target:

  Apoptosis; c-Myc; FAK; MDM-2/p53; Mitosis; Src; TOPK

• Related Pathways:

  Apoptosis; Cell Cycle/DNA Damage; Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Smiles:

  O=C1NC2=C(C)C=C(O)C(C3=CC=C(C=C3)[C@H](CN)C)=C2C4=C1C=CC=C4.Cl

• Molecular Formula:

  C23H23ClN2O2

• Molecular Weight:

  394.89

• References & Citations:

  [1]Gao T, et al. Novel selective TOPK inhibitor SKLB-C05 inhibits colorectal carcinoma growth and metastasis. Cancer Lett. 2019 Mar 31;445:11-23.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [2300981-68-2]